OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval ...

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell ...

Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 61.6% Wednesday after the FDA approved YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated ...

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...